BPG is committed to discovery and dissemination of knowledge
Review
Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Gastrointest Pharmacol Ther. Jun 5, 2026; 17(2): 114292
Published online Jun 5, 2026. doi: 10.4292/wjgpt.v17.i2.114292
Beyond gluten-free diet: Novel therapeutic frontiers in celiac disease armamentarium
Sandeep K Mundhra, Rakesh K Kochhar
Sandeep K Mundhra, Department of Gastroenterology, Geetanjali Medical College and Hospital, Udaipur 313001, Rājasthān, India
Rakesh K Kochhar, Department of Gastroenterology, Paras Hospital, Panchkula 134109, Haryana, India
Rakesh K Kochhar, Department of Gastroenterology, National Institute of Medical Sciences, Jaipur 303121, Rājasthān, India
Author contributions: Mundhra SK and Kochhar RK designed the overall concept and outline of the manuscript; Mundhra SK contributed to the literature review, writing and editing of the manuscript; Kochhar R supervised the literature search and writing, provided intellectual input and critically revised the manuscript; and all authors thoroughly reviewed and endorsed the final manuscript.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Corresponding author: Rakesh K Kochhar, DM, Professor, Department of Gastroenterology, Paras Hospital, Paras Hospital Road, Sector-22, Panchkula 134109, Haryana, India. dr_kochhar@hotmail.com
Received: September 16, 2025
Revised: December 1, 2025
Accepted: February 3, 2026
Published online: June 5, 2026
Processing time: 253 Days and 22.3 Hours
Core Tip

Core Tip: Celiac disease is managed with a gluten-free diet, which is difficult to sustain and often fails to achieve full mucosal recovery. Advances in disease pathogenesis have led to novel therapies, including gluten-detoxifying enzymes, gluten-sequestering polymers, barrier stabilizers, tissue transglutaminase-2 inhibitors, human leukocyte antigen-DQ antagonists, cytokine-directed biologics, and tolerance-inducing strategies such as nanoparticle-based therapies. This review summarizes the current therapeutic pipeline, discusses the challenges of translating emerging therapies into routine practice, and highlights how future management is likely to evolve towards personalized, multimodal approaches that integrate dietary management with safe and effective adjunctive therapies.

Write to the Help Desk